237 related articles for article (PubMed ID: 23529741)
1. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
3. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
4. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients.
Karthaus M; Doellmann T; Klimasch T; Elser C; Rosenthal C; Ganser A; Heil G
Chemotherapy; 2000; 46(4):293-302. PubMed ID: 10859435
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
[TBL] [Abstract][Full Text] [Related]
6. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
8. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
9. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
10. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
Giannella M; Ercolani G; Cristini F; Morelli M; Bartoletti M; Bertuzzo V; Tedeschi S; Faenza S; Puggioli C; Lewis RE; Pinna AD; Viale P
Transplantation; 2015 Apr; 99(4):848-54. PubMed ID: 25531982
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.
Gubbins PO; Amsden JR; McConnell SA; Anaissie EJ
Antimicrob Agents Chemother; 2009 Sep; 53(9):3664-74. PubMed ID: 19546359
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.
Sunakawa K; Tsukimoto I; Tsunematsu Y; Honda M; Iwai N; Maniwa T; Haigo H; Suzuki K; Mori T
J Infect Chemother; 2012 Aug; 18(4):456-65. PubMed ID: 22286407
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.
Seibel NL; Shad AT; Bekersky I; Groll AH; Gonzalez C; Wood LV; Jarosinski P; Buell D; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855062
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Döring M; Hartmann U; Erbacher A; Lang P; Handgretinger R; Müller I
BMC Infect Dis; 2012 Jul; 12():151. PubMed ID: 22747637
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
Cornely OA; Leguay T; Maertens J; Vehreschild MJGT; Anagnostopoulos A; Castagnola C; Verga L; Rieger C; Kondakci M; Härter G; Duarte RF; Allione B; Cordonnier C; Heussel CP; Morrissey CO; Agrawal SG; Donnelly JP; Bresnik M; Hawkins MJ; Garner W; Gökbuget N;
J Antimicrob Chemother; 2017 Aug; 72(8):2359-2367. PubMed ID: 28575414
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
Javandoust Gharehbagh F; Roshanzamiri S; Farjami M; Hatami F; Lotfollahi L; Kazeminia N; Hatami F; Shokouhi S; Alavi Darazam I
J Oncol Pharm Pract; 2024 Jul; 30(5):919-929. PubMed ID: 38720564
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation.
Umemura K; Katada Y; Nakagawa S; Hira D; Yutaka Y; Tanaka S; Ohsumi A; Nakajima D; Date H; Nagao M; Terada T
J Infect Chemother; 2024 Aug; 30(8):741-745. PubMed ID: 38354908
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis.
Hand EO; Ramanathan MR
Pediatr Infect Dis J; 2014 Aug; 33(8):835-6. PubMed ID: 25222303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
